Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Edwards Lifesciences will report Q1 2026 results after the market closes on April 22, with analysts forecasting $0.728 EPS and $1.5965 billion in revenue and the company guiding to $0.70–$0.76 EPS.
• In the prior quarter Edwards missed EPS ($0.58 vs. $0.62) while revenue grew 13.3% year-over-year to $1.57 billion; analysts expect roughly $2 in EPS for the current fiscal year and $3 for the next.
• The stock trades around $78 with a ~$45.1 billion market cap and a 42.7 P/E, carries a consensus "Moderate Buy" rating and $95.74 target, and has seen recent insider selling (86,058 shares worth about $7.1M over three months).

Edwards Lifesciences (NYSE:EW - Get Free Report) will likely be issuing its Q1 2026 results after the market closes on Wednesday, April 22nd. Analysts expect the company to announce earnings of $0.7280 per share and revenue of $1.5965 billion for the quarter. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 22, 2026 at 5:00 PM ET.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business's revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.59 earnings per share. On average, analysts expect Edwards Lifesciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $78.21 on Wednesday. The stock has a market cap of $45.09 billion, a P/E ratio of 42.74, a price-to-earnings-growth ratio of 2.04 and a beta of 0.95. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The stock's 50-day moving average is $81.25 and its 200-day moving average is $82.08. Edwards Lifesciences has a 1-year low of $68.63 and a 1-year high of $87.89.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EW. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the stock an "outperform" rating in a research report on Monday. Robert W. Baird set a $90.00 price objective on Edwards Lifesciences in a research report on Monday, January 12th. UBS Group restated a "neutral" rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $95.74.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the sale, the vice president directly owned 33,934 shares in the company, valued at approximately $2,747,975.32. The trade was a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the sale, the vice president owned 21,266 shares of the company's stock, valued at approximately $1,704,682.56. The trade was a 51.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 86,058 shares of company stock worth $7,118,636. 0.31% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds have recently added to or reduced their stakes in EW. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter worth approximately $25,000. Kemnay Advisory Services Inc. bought a new stake in Edwards Lifesciences in the fourth quarter worth approximately $27,000. Rakuten Securities Inc. increased its holdings in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Kelleher Financial Advisors bought a new stake in Edwards Lifesciences in the third quarter worth approximately $50,000. Finally, Chapman Financial Group LLC bought a new stake in Edwards Lifesciences in the second quarter worth approximately $63,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.